Nano Particulate Carriers in Drug Delivery System: A Review

Authors

  • Ashish Kumar Varma Assistant Professor, Pranveer Singh Institute of Technology, Kanpur, U.P., India.
  • Ashish Srivastava Assistant Professor, Pranveer Singh Institute of Technology, Kanpur, U.P., India.
  • Swatantra Kushwaha Assistant Professor, Pranveer Singh Institute of Technology, Kanpur, U.P., India.

Keywords:

drug delivery; nanotechnology; nanomedicine

Abstract

Nano particle has been widely considered as particulate carrier in the pharmaceutical fields, because they show promise as drug delivery systems as a result of their controlled and sustained-release properties and biocompatibility with the tissue and cells.

In the large field of nanotechnology, polymer matrix-based nano composites have become an important area of existing research and development. This review will spotlight on the progress of nano scale drug delivery mechanisms. Nano structured drug carriers’ permit for the delivery of not only small-molecule drugs but also the delivery of nucleic acids and proteins. Delivery of these molecules to specific areas within the body can be achieved, which will reduce systemic side effects and allow for more competent use of the drug.

References

1. Bailey RE, Smith AM, Nie S. Quantum dots in biology
and medicine. Physica E 2004; 25: 1-12.
2. Bhadra D, Bhadra S, Jain NK. Pegylated lysine based
copolymeric dendritic micelles for solubilization and
delivery of artemether. J Pharm Pharm Sci 2005; 8:
467-482.
3. Bhalekar MR, Pokharkar V, Madgulkar A et al.
Preparation and evaluation of miconazole nitrateloaded
solid lipid nanoparticles for topical delivery.
AAPS PharmSciTech 2009; 10: 289-296.
4. Brannon-Peppas L, Blanchette JO. Nanoparticle and
targeted systems for cancer therapy. Adv Drug Delivery
Rev 2004; 56: 1649-1659.
5. Cevc G. Lipid vesicles and other colloids as drug carriers
on the skin. Adv Drug Deliv Rev 2004; 56: 675-711.
6. Chen Y, Dalwadi G, Benson H. Drug delivery across
the blood-brain barrier. Current Drug Delivery 2004;
1: 361-376.
7. Davis SS. Commentary, coming of age of lipid-based
drug delivery systems. Adv Drug Deliv Rev 2001; 56:
1241-1242.
8. Desai MP. Gastrointestinal uptake of biodegradable
microparticles: effect of particle size. Pharm Res 1996;
13; 1838-1845.
9. Desai MP. Gastrointestinal uptake of biodegradable
microparticles: effect of particle size. Pharm Res 1996;
13: 1838-1845.
10. Devarakonda B, Hill RA, Liebenberg W et al. Comparison
of the aqueous solubilization of practically insoluble
niclosamide by polyamidoamine (PAMAM) dendrimers
and cyclodextrins. Int J Pharm 2005; 304: 193-209.
11. Ferrari M. Cancer nanotechnology: opportunities and
challenges. Nature Reviews/ Cancer 2005 5: 161-171.
12. Florence AT, Hussain N. Transcytosis of nanoparticle
and dendrimer delivery systems: evolving vistas. Adv
Drug Deliv Rev 2001; 50: 1: S69-89.
13. Grazia Cascone M, Zhu Z, Borselli F et al. Poly(vinyl
alcohol) hydrogels as hydrophilic matrices for the
release of lipophilic drugs loaded in PLGA nanoparticles
J Mat Sci Mat Med 2002; 13: 29-32.
14. Hussain A, Ahsan F. The vagina as a route for systemic
drug delivery. J Control Release 2005; 103: 301-313.
15. Hussain M, Shchepinov M, Sohail M et al. A novel
anionic dendrimer for improved cellular delivery of
antisense oligonucleotides. J Controlled Release 2004;
99: 139-155.
16. Jain KK. The role of nanobiotechnology in drug
discovery. Drug Discovery Today 2005; 10(21): 1435-
1442.
17. Jain KK. Use of nanoparticles for drug delivery in
glioblastoma multiforme. Exp Rev Neurother 2007;
7: 363-337.
18. Jain S, Jain NK. Liposomes as drug carrier. Jain NK.
(Ed.): Controlled and Novel Drug Delivery, 2nd ed.,
CBS Publisher, New Delhi. 2002; 304-352.
19. Jallouli Y, Paillard A, Chang J et al. Influence of surface
charge and inner composition of porous nanoparticles
to cross blood-brain barrier in vitro. Int J Pharmaceutics
2007; 344: 103-110.
20. Kim HJ, Jones MN. The delivery of benzyl penicillin to
staphylococcus aureus biofilms by use of liposomes J
Liposome Res 2004; 14: 123-139.
21. Kohli AK, Alpar HO. Potential use of nanoparticles for
transcutaneous vaccine delivery: effect of particle size
and charge. Int J Pharm 2004; 275: 13-17.
22. Kubik T, Bogunia-Kubik K, Sugisaka M. Nanotechnology
on duty in medical applications. Current Pharmaceutical
Biotechnology 2005; 6: 17-33.
23. Kumar N, Ravikumar MNV, Domb AJ. Biodegradable
block copolymers. Adv Drug Deliv Rev 2001; 53: 23-44.
24. Lu Y, Chen SC. Micro and nano-fabrication of
biodegradable polymers for drug delivery. Adv Drug
Deliv Rev 2004; 56: 1333-162.
25. Müller RH, Mäder K, Gohla S. Solid lipid nanoparticles
(SLN) for controlled drug delivery, a review of the state
of the art. Eur J Pharm Biopharm 2000; 50: 161-177.
26. Nahar M, Dutta T, Murugesan S et al. Functional
polymeric nanoparticles: an efficient and promising
tool for active delivery of bioactives. Crit Rev Ther
Drug Carrier Syst 2006; 23: 4: 259-318.
27. Patil GV. Biopolymer albumin for diagnosis and in drug
delivery. Drug Dev Res 2003; 58: 219-247.
28. Ravi Kumar MN. Nano and microparticles as controlled
drug delivery devices. J Pharm Pharm Sci 2000; 3:
234-258.
29. Senthilkumar M, Subramanian G, Ranjitkumar A
et al. PEGylated Poly (Lactide-co-Glycolide) (PLGA)
nanoparticulate delivery of docetaxel: synthesis of
diblock copolymers, optimization of preparation
variables on formulation characteristics and in vitro
release studies. J Biomed Nanotech 2007; 1: 52-60.
30. Serpe L, Catalano MG, Cavalli R et al. Cytotoxicity
of anticancer drugs incorporated in solid lipid
nanoparticles HT-29 colorectal cancer cell line. Eur J
Pharm Biopharm 2004; 58: 673-680.
31. Sinha N, Yeow JTW. Carbon nanotubes for biomedicalapplications. IEEE Transactions on Nanobioscience
2005; 4(2): 180-195.
32. Sinha VR, Trehan A. Biodegradable microspheres for
protein delivery. J Control Release 2003; 90: 261-280.
33. Smart JD. Buccal drug delivery. Expert Opin Drug Deliv
2005; 2: 507-517.
34. Souto EB, Muller RH. SLN and NLC for topical delivery
of ketoconazole. J Microencapsul 2005; 22: 501-510.
35. Svenson S. Dendrimers versatile platform in drug delivery
applications. European Journal of Pharmaceutics and
Biopharmaceutics 2009; 71: 445-462.
36. Tao SL, Desai TA. Microfabricated drug delivery systems:
from particles to pores. Adv Drug Delivery Rev 2003;
55: 315-328.
37. Tu RS, Tirrell M. Bottom-up design of biomimetic
assemblies. Adv Drug Deliv Rev 2004; 56: 1537-1563.
38. Vasir JK, Reddy MK, Labhasetwar VD. Nanosystems in
drug targeting: opportunities and challenges. Current
Nanoscience 2005; 1: 47-64.
39. Venugopal J, Prabhakaran MP, Low S et al. Continuous
nanostructures for the controlled release of drugs.
Curr Pharm Des 2009; 15: 1799-1808.
40. Wang W. Instability, stabilization, and formulation
of liquid protein pharmaceuticals. Int J Pharm 1999;
185: 129-188.
41. Wickline SA, Lanza GM. Molecular imaging, targeted
therapeutics, and nanoscience. J Cellular Biochem
2002; 39: 90-97.
42. Zhang L, Pornpattananangku D. Hu CM et al.
Development of nanoparticles for antimicrobial drug
delivery. Curr Med Chem 2010; 17(6): 585-594.

Downloads

Published

2019-02-23

How to Cite

Varma, A. K., Srivastava, A., & Kushwaha, S. (2019). Nano Particulate Carriers in Drug Delivery System: A Review. Journal of Drug Discovery and Development ( ISSN:2581-6861), 2(2), 19-25. Retrieved from https://medicaljournalshouse.com/index.php/JDrug-Discovery-Development/article/view/79

Issue

Vol. 2 No. 2 (2018): Journal of Drug Discovery and Development

Section

Review Article

License

We, the undersigned, give an undertaking to the following effect with regard to our article entitled
“_______________________________________________________________________________________________________________________________________________________________________________
________________________________________________________________________________” submitted for publication in (Journal title)________________________________________________ _______________________________________________________Vol.________, Year _________:-

1. The article mentioned above has not been published or submitted to or accepted for publication in any form, in any other journal.

2. We also vouchsafe that the authorship of this article will not be contested by anyone whose name(s) is/are not listed by us here.

3. I/We declare that I/We contributed significantly towards the research study i.e., (a) conception, design and/or analysis and interpretation of data and to (b) drafting the article or revising it critically for important intellectual content and on (c) final approval of the version to be published.

4. I/We hereby acknowledge ADRs conflict of interest policy requirement to scrupulously avoid direct and indirect conflicts of interest and, accordingly, hereby agree to promptly inform the editor or editor's designee of any business, commercial, or other proprietary support, relationships, or interests that I/We may have which relate directly or indirectly to the subject of the work.

5. I/We also agree to the authorship of the article in the following sequence:-

Authors' Names (in sequence) Signature of Authors
1. _____________________________________ _____________________________________
2. _____________________________________ _____________________________________
3. _____________________________________ _____________________________________
4. _____________________________________ _____________________________________
5. _____________________________________ _____________________________________
6. _____________________________________ _____________________________________
7. _____________________________________ _____________________________________
8. _____________________________________ _____________________________________

Important

(I). All the authors are required to sign independently in this form in the sequence given above. In case an author has left the institution/ country and whose whereabouts are not known, the senior author may sign on his/ her behalf taking the responsibility.

(ii). No addition/ deletion/ or any change in the sequence of the authorship will be permissible at a later stage, without valid reasons and permission of the Editor.

(iii). If the authorship is contested at any stage, the article will be either returned or will not be
processed for publication till the issue is solved.